GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (NAS:FLGT) » Definitions » Cash Flow from Financing

FLGT (Fulgent Genetics) Cash Flow from Financing : $-4.8 Mil (TTM As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Fulgent Genetics Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2024, Fulgent Genetics paid $0.2 Mil more to buy back shares than it received from issuing new shares. It spent $0.1 Mil paying down its debt. It paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.0 Mil from paying cash dividends to shareholders. It received $0.1 Mil on other financial activities. In all, Fulgent Genetics spent $0.3 Mil on financial activities for the three months ended in Dec. 2024.


Fulgent Genetics Cash Flow from Financing Historical Data

The historical data trend for Fulgent Genetics's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Cash Flow from Financing Chart

Fulgent Genetics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 261.25 85.41 -77.14 -47.79 -4.85

Fulgent Genetics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.95 -2.81 -1.15 -0.57 -0.33

Fulgent Genetics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Fulgent Genetics's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:

Fulgent Genetics's Cash from Financing for the quarter that ended in Dec. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fulgent Genetics  (NAS:FLGT) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Fulgent Genetics's issuance of stock for the three months ended in Dec. 2024 was $0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Fulgent Genetics's repurchase of stock for the three months ended in Dec. 2024 was $-0.2 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Fulgent Genetics's net issuance of debt for the three months ended in Dec. 2024 was $-0.1 Mil. Fulgent Genetics spent $0.1 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Fulgent Genetics's net issuance of preferred for the three months ended in Dec. 2024 was $0.0 Mil. Fulgent Genetics paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Fulgent Genetics's cash flow for dividends for the three months ended in Dec. 2024 was $0.0 Mil. Fulgent Genetics received $0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Fulgent Genetics's other financing for the three months ended in Dec. 2024 was $0.1 Mil. Fulgent Genetics received $0.1 Mil on other financial activities.


Fulgent Genetics Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Fulgent Genetics Business Description

Traded in Other Exchanges
Address
4399 Santa Anita Avenue, El Monte, CA, USA, 91731
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Executives
Paul Kim officer: CFO and Treasurer 4399 SANTA ANITA AVE, EL MONTE CA 91731
Hanlin Gao 10 percent owner, officer: Chief Scientific Officer 4399 SANTA ANITA AVE., EL MONTE CA 91731
Jian Xie officer: Chief Operating Officer C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVE, EL MONTE CA 91731
Ming Hsieh director, 10 percent owner, officer: President and CEO 4399 SANTA ANITA AVE., EL MONTE CA 91731
Regina E Groves director 5751 COPLEY DRIVE, SAN DIEGO CA 92111
Leonard E Post director
Michael Nohaile director C/O BIO AI ACCELERATION COMPANY, 20 UNIVERSITY AVENUE, CAMBRIDGE MA 02138
John C Bolger director 4978 SANTA ANITA AVENUE, SUITE 205, TEMPLE CITY CA 91780
Ming Hsieh Trust 10 percent owner 4399 SANTA ANITA AVE., EL MONTE CA 91731
Linda Marsh director 100 N. STONEMAN AVE., ROOM 200, ALHAMBRA CA 91801
Fulgent Genetics, Inc. director 4399 SANTA ANITA AVE, EL MONTE CA 91731
Yun Yen director 1301 OAKLAWN ROAD, ARCADIA CA 91006
James Mulay director 6521 THOROUGHBRED LOOP, ODESSA FL 33556
Xi Long Usa, Inc. 10 percent owner #6 XINRUI RD., SCIENCE CITY, LUOGANG DISTRICT, GUANGZHOU CITY F4 510663